<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283659</url>
  </required_header>
  <id_info>
    <org_study_id>Project I-C</org_study_id>
    <secondary_id>CIF-99470</secondary_id>
    <nct_id>NCT01283659</nct_id>
    <nct_alias>NCT01622985</nct_alias>
  </id_info>
  <brief_title>IMAGE-HF Project I-C: Computed Tomographic Coronary Angiography for Heart Failure Patients</brief_title>
  <acronym>CTA-HF</acronym>
  <official_title>Computed Tomographic Coronary Angiography for Heart Failure Patients (CTA -HF) Project I-C of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Finnish Funding Agency for Technology and Innovation (TEKES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The prevalence of heart failure (HF) is rapidly rising in industrialized and
      developing countries. Though invasive coronary angiography (ICA) remains the gold standard
      for anatomical assessment of coronary arteries and luminal stenoses in these patients,
      alternatives have been sought. Computed tomographic coronary angiography (CTA) has emerged as
      an accurate non-invasive diagnostic tool for CAD and has been demonstrated to have prognostic
      value. Whether or not CTA can be used in patients with HF for diagnosis and to guide patient
      investigations and management is unknown. Acknowledging the aging population in
      industrialized counties, the increasing burden of healthcare and growing prevalence of HF,
      there is a need to identify non-invasive diagnostic tests that are cost-effective, readily
      available, safe and of sufficient accuracy to risk stratify patients and guide investigations
      and management.

      Methods: The proposed randomized controlled trial (RCT) will evaluate the clinical utility of
      computed tomographic coronary angiography (CTA) and investigate its potential benefit on
      resource utilization and health economics in patients with progressive or newly diagnosed
      heart failure (HF) of unknown etiology (i.e. ischemic versus non- ischemic) or in whom the
      definition of coronary anatomy is required for diagnosis and management. The experimental
      algorithm will be compared to invasive coronary angiography (ICA)

      Analysis of composite clinical events and major adverse cardiac events will be performed to
      determine the impact of these strategies upon patient outcomes. Accuracy of CTA in detection
      of coronary anatomy and obstruction will be assessed in patients undergoing ICA. It is
      expected that CTA will be a more cost-effective strategy for diagnosis; yielding similar
      outcomes with fewer procedural risks and improved resource utilization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses Primary Hypothesis: Compared to ICA, a diagnostic strategy algorithm using CTA for
      patients with HF of unknown etiology or where the definition of coronary anatomy is required
      for diagnosis and management, will result in a reduction in downstream resource utilization
      and per patient cost.

      Secondary Hypotheses: I) Compared to standard care, a strategy that uses CTA will achieve: a)
      similar composite clinical events (CCE), quality of life (QoL), major adverse cardiac events
      (MACE); b) a lower rate of procedure related complications (death, MI, stroke, vascular
      complications, severe allergic reactions; contrast nephropathy); c) a lower rate of normal
      ICA. II) Using patient-based analysis and vessel-based analysis, CTA has very good agreement
      with ICA among patients with HF in the CTA arm who proceed to ICA.

      Objectives The primary objective is to understand the role of CTA in patients with HF of
      unknown etiology. We propose a prospective randomized study of 250 patients to examine the
      potential impact of CTA compared to ICAon resource utilization and health care costs in
      patients with HF with unknown CAD status.

      Secondary objectives are to: compare CCE, QoL and MACE in the CTA and ICA arms. Radiation
      exposure and safety in both groups will also be assessed.

      Trial design The proposed trial is a multicentre randomized controlled trial of 250 patients.
      In addition, a retrospective review of the current CTA and ICA databases at the University of
      Ottawa Heart Institute will be conducted to identify an additional cohort of patients
      (200-400) where the imaging modality decision has already been made. These patients are not
      eligible for randomization, but will be entered into a registry.

      Trial interventions - Randomization All HF patients requiring investigation to determine the
      etiology of HF (ischemic versus non-ischemic) will be screened for the study. Patients will
      be randomized to the investigation arm CTA or ICA. Patients will be stratified according to
      recruitment site and pre-test probability for obstructive CAD. A stratified block (varying
      sizes) randomization scheme will be used. Within each strata, patients will be randomized
      with varying block sizes into the two study groups. A central randomization scheme
      (envelope), which will ensure concealment, will be used and the local research co-ordinator
      will perform patient assignments. The randomization scheme will be generated by a
      statistician using a SAS macro.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resource Utilization</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Primary Outcome Measure: Resource Utilization: will be measured as detailed in Appendix A. Cost: the incremental cost of the diagnostic strategy using CTA will be the primary endpoint and will be estimated through regression methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Endpoints</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>CCE, LV Function, QoL, and Safety: will measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTA Accuracy</measure>
    <time_frame>Baseline</time_frame>
    <description>CTA Accuracy: To address one of the secondary hypotheses: the accuracy in the cohort of patients with CTA undergoing ICA (~ n=100) diagnostic test characteristics (sensitivity, specificity, predictive values and likelihood ratios) will be determined and reported with 95% confidence intervals (CI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Standard imaging (coronary angiography)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo a coronary angiogram as planned by their attending doctor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced imaging (CTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Imaging</intervention_name>
    <arm_group_label>Standard imaging (coronary angiography)</arm_group_label>
    <other_name>Coronary Angiography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Advanced Imaging</intervention_name>
    <arm_group_label>Advanced imaging (CTA)</arm_group_label>
    <other_name>Coronary Computed Tomographic Angiography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Eligible HF patients with an admission to hospital or emergency room for
        heart failure

        OR

        a documented history of left ventricular dysfunction (LVEF &lt;50%)

        OR

        a documented history of Class ll-lV heart failure symptoms, in the preceding 12 months
        prior to enrollment, in whom the diagnosis of CAD is uncertain or the definition of
        coronary anatomy is required for diagnosis and management.

        Exclusion criteria:

          1. Age &lt; 18 years or lack of consent,

          2. Renal Insufficiency (GFR &lt; 45 ml/min);

          3. Allergy to intravenous contrast agents;

          4. Contraindication to radiation exposure (e.g. pregnancy);

          5. Uncontrolled HR at time of scan (as per local clinical routine)

          6. History of revascularization (CABG or PCI);

          7. Atrial fibrillation, frequent atrial or ventricular ectopy (&gt; 1 / minute);

          8. Unable to perform 20 second breath-hold;

          9. CTA or ICA within the preceding 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob SB Beanlands, MD, FRCP C</last_name>
    <role>Study Director</role>
    <affiliation>University of OttawaHeart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Chow, MD, FRCP C</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√© de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital,</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kuopio</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Paterson DI, OMeara E, Chow BJ, Ukkonen H, Beanlands RS. Recent advances in cardiac imaging for patients with heart failure. Curr Opin Cardiol. 2011 Mar;26(2):132-43. doi: 10.1097/HCO.0b013e32834380e7. Review.</citation>
    <PMID>21297464</PMID>
  </reference>
  <reference>
    <citation>Chow BJ, Green RE, Coyle D, Laine M, Hanninen H, Leskinen H, Rajda M, Larose E, Hartikainen J, Hedman M, Mielniczuk L, O'Meara E, deKemp RA, Klein R, Paterson I, White JA, Yla-Herttuala S, Leber A, Tandon V, Lee T, Al-Hesayen A, Hessian R, Dowsley T, Kass M, Kelly C, Garrard L, Tardif JC, Knuuti J, Beanlands RS, Wells GA; IMAGE-HF Investigators. Computed tomographic coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE HF Project 1-C). Trials. 2013 Dec 26;14:443. doi: 10.1186/1745-6215-14-443.</citation>
    <PMID>24369097</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2011</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Rob Beanlands</investigator_full_name>
    <investigator_title>Rob S. Beanlands, MD, FRCPC, Chief of Cardiology</investigator_title>
  </responsible_party>
  <keyword>computed tomographic angiography</keyword>
  <keyword>coronary angiogram</keyword>
  <keyword>cost effectiveness</keyword>
  <keyword>QoL</keyword>
  <keyword>Heart failure</keyword>
  <keyword>diagnostic accuracy</keyword>
  <keyword>prospective comparative effectiveness randomized clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

